Miskelly, Michael G. http://orcid.org/0000-0002-4688-5719
Lindqvist, Andreas http://orcid.org/0009-0000-8287-5609
Piccinin, Elena http://orcid.org/0000-0002-6514-2689
Hamilton, Alexander http://orcid.org/0000-0001-5203-9220
Cowan, Elaine http://orcid.org/0000-0003-3939-8864
Nergård, Bent-Johnny
Del Giudice, Rita http://orcid.org/0000-0002-9927-9413
Ngara, Mtakai http://orcid.org/0000-0001-5018-4387
Cataldo, Luis R. http://orcid.org/0000-0003-1225-414X
Kryvokhyzha, Dmytro http://orcid.org/0000-0001-6498-1977
Volkov, Petr
Engelking, Luke http://orcid.org/0000-0002-1355-4964
Artner, Isabella http://orcid.org/0000-0002-2895-5664
Lagerstedt, Jens O. http://orcid.org/0000-0002-4313-2666
Eliasson, Lena http://orcid.org/0000-0002-6467-5029
Ahlqvist, Emma http://orcid.org/0000-0002-6513-2384
Moschetta, Antonio http://orcid.org/0000-0003-2123-6074
Hedenbro, Jan http://orcid.org/0000-0001-7479-9087
Wierup, Nils http://orcid.org/0000-0001-6824-4093
Funding for this research was provided by:
Vetenskapsrådet (2020-01017, 2017-00862, 521-2012-2119)
Lund University
Article History
Received: 22 May 2023
Accepted: 15 September 2023
First Online: 30 November 2023
Acknowledgements
: The authors would like to thank M. Sterner and M. Neptin (Lund University Diabetes Centre [LUDC], Lund University, Sweden) for their technical assistance in performing RNA-seq. We also thank the LUDC Bioinformatics Unit (ExternalRef removed; Lund University, Sweden) for providing bioinformatics, biostatistics and computational support, as well as access to a high-performance computing environment.
: All data are available from the corresponding author on request.
: Open access funding provided by Lund University. NW is supported by the Swedish Research Council (2020-01017, 2017-00862 and 521-2012-2119), regional research foundation Avtal om Läkarutbildning och Forskning (ALF), Diabetes Wellness Research Foundation Sweden, Albert Påhlsson Foundation, Royal Physiographic Society in Lund and Swedish Diabetes Foundation. Lund University Diabetes Centre is supported by the Swedish Research Council, Linnaeus grant (Dnr 349-2006-237), Strategic Research Area Exodiab (Dnr 2009-1039) and the Swedish Foundation for Strategic Research (Dnr IRC15-0067). JOL is supported by the Swedish Research Council (2020-02179).
: Jens O. Lagerstedt is an employee at Novo Nordisk A/S, Denmark. Petr Volkov is an employee at AstraZeneca AB. The authors declare that there are no other relationships or activities that might bias, or be perceived to bias, their work.
: Data acquisition was performed by MGM, AL, EP, AH, EC, RDG, MN, LRC, DK and PV. Data were analysed and interpreted by MGM, AL, AH, EC, RDG, MN, DK, PV, LEn, IA, JOL, LEl, EA and NW. Study conception and design was undertaken by MGM, AL, B-JN, AM, JH and NW, EP and AM provided i<i>Scd1</i><sup>−/−</sup> mice and serum and tissue samples. The original draft of this article was written and revised by MGM, AL and NW. Funding was provided by NW, who is also guarantor of the data. The manuscript was revised by all authors and all authors approved the final draft of the manuscript.